Compare PRAX & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | EXLS |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 5.1B |
| IPO Year | 2020 | 2004 |
| Metric | PRAX | EXLS |
|---|---|---|
| Price | $299.14 | $30.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $572.13 | $46.80 |
| AVG Volume (30 Days) | 309.6K | ★ 2.1M |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ 1.54 |
| Revenue | N/A | ★ $2,087,679,000.00 |
| Revenue This Year | N/A | $12.85 |
| Revenue Next Year | $6,395.88 | $10.65 |
| P/E Ratio | ★ N/A | $19.87 |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $26.70 | $26.94 |
| 52 Week High | $354.87 | $48.79 |
| Indicator | PRAX | EXLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 43.45 |
| Support Level | $290.36 | $28.62 |
| Resistance Level | $322.32 | $32.98 |
| Average True Range (ATR) | 16.93 | 0.99 |
| MACD | -3.50 | 0.25 |
| Stochastic Oscillator | 22.92 | 40.38 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.